The Gustave Roussy Haematology Committee is responsible for management of patients with bone marrow and lymph node diseases (malignant blood diseases):
Molecular medicine – or personalised medicine, still called precision medicine, – is based on a new approach to diagnosis, known as molecular diagnosis, which depends on analysis of the tumour genome. According to the results of this analysis, targeted drugs tailored to the genetic profile are tried. The objective is to be able to offer each patient drugs which are specifically targeted to the genetic profile of the tumour.